BRCA2 and ovarian carcinoma: BRCA2-deficient cancer cells are hypersensitive to DNA-crosslinking agents including cisplatin [13], as a consequence, women with BRCA1/2-mutated ovarian carcinoma have a better diagnosis than those without BRCA1/2- mutation if they receive platinum-based therapy [14].